Dr. Mittendorf on QoL With Neoadjuvant Atezolizumab/Chemo in Early TNBC

Partner | Cancer Centers | <b>Dana Farber</b>

Elizabeth A. Mittendorf, MD, PhD, discusses patient-reported quality of life associated with neoadjuvant atezolizumab plus chemotherapy in early triple-negative breast cancer.

Elizabeth A. Mittendorf, MD, PhD, Rob and Karen Hale Distinguished Chair in Surgical Oncology, Brigham and Women's Hospital, director of surgical research, director of Breast Immuno-Oncology Program, and co-director of the Breast Cancer Clinical Research Program at Dana-Farber Cancer Institute, discusses patient-reported quality of life (QoL) associated with neoadjuvant atezolizumab (Tecentriq) plus chemotherapy in early triple-negative breast cancer (TNBC).

The patients-reported outcomes from the phase 3 IMpassion031 study (NCT03197935) helped to clarify the QoL for those undergoing treatment with the atezolizumab/chemotherapy regimen, says Mittendorf. 

Importantly, when examining domains detailed in the report, such as treatment-related symptoms, symptom bother, role function, physical function, emotional and social function, and health-related quality of life, a decrease in baseline QoL was observed; however, this increased again as patients completed treatment, adds Mittendorf.

This appears to be comparable in both arms of the trial, which may indicate that patients who received the immunotherapy agent did not experience a significant decrease in QoL, concludes Mittendorf.